Panel Discussion: Recognizing Novel & Emerging Biomarkers of Significance to Help Identify Populations for Clinical Trial Studies, Monitor Therapeutic Response & Identify Side Effects

Time: 4:00 pm
day: Day One


  • How do we reduce the need for DBPCFC (double-blind placebo-controlled food challenge) for clinical assessment?
  • Developing biomarkers that are informative of key clinical parameters of food allergy, including threshold of reactivity, risk of severe reactions, probability of natural resolution, and probability of successful treatment response to immunotherapy
  • How do we bring about the shift to test the utility of novel biomarkers for use in guiding clinical care rather than a research tool?